The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells

Cancer Gene Therapy

Volumn 14, Issue 4, 2007, Pages 431-439

  Neukirchen, J ^a   Meier, A ^a   Rohrbeck, A ^a   Garcia Pardillos, G ^a   Steidl, U ^b   Fenk, R ^a   Haas, R ^a   Kronenwett, R ^a   Rohr, U P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Bortezomib; Docetaxel; Pemetrexed; rRAAV p53

Indexed keywords

BORTEZOMIB; DOCETAXEL; PARVOVIRUS VECTOR; PEMETREXED; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; EMBRYO; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; GENE THERAPY; GENES, P53; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TAXOIDS; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENO-ASSOCIATED VIRUS - 2;

EID: 33947230813     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701029     Document Type: Article

References (41)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 45: 8-29.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. Engels FK, Sparreboom A, Mathot RAA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005; 93:173-177.
4. Adjei AA. Pemetrexed (Alimta), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004; 10: 4276-4280.
5. Hanna N, Sheperd F, Rosell R, Pereira JR, De Marinis F, Fossella F et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously treated with chemotherapy. Am Soc Clin Oncol 2003; 22: 622.
6. Roth JA, Grammer SF. Gene replacement therapy for nonsmall cell lung cancer: a review. Hematol Oncol Clin N Am 2004; 18: 215-229.
7. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Nat Cancer Inst 1999; 91: 763-771.
8. Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C. The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 2004; 51: 29-44.
9. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.
10. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104: 1794-1807.
11. Scagliotti G. Proteasome inhibition in lung cancer. Crit Rev Oncol Hematol 2006; 58: 177-189.
12. Adams J. The proteasome: structure, function and role in the cell. Cancer Treat Rew 2003; 29: 3-9.
13. 2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-1154.
14. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54: 343-353.
15. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95: 176-180.
16. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000; 11: 239-246.
17. Lopes UG, Erhardt P, Yao R, Cooper GM. P53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893-12896.
18. Ren J, Shi M, Liu R, Yang Q-H, Johnson T, Skarnes WC et al. The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci 2005; 102: 565-570.
19. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S et al. P53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-180.
20. Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R et al. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector. Cancer Gene Ther 2003; 10: 898-906.
21. Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 2002; 106: 81-89.
22. Hö rster A, Teichmann B, Hormes R, Grimm D, Kleinschmidt J, Sczakiel G. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression and show anti-HIV-1 efficacy. Gene Therapy 1999; 6: 1231-1238.
23. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Therapy 1998; 9: 2745-2760.
24. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
25. Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G et al. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods 2005; 127: 40-45.
26. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Valent A, Benard J et al. p73 functionally replaces p53 in adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005; 116: 860-869.
27. Richardson PG, Hideshima T, Anderson KC. Bortezomib: a novel, first-in-class proteasome inhibitor for the treatment of multiple meyloma and other cancers. Cancer Control 2005; 10: 361-369.
28. Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer. Mol Biotech 2003; 24: 141-156.
29. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and novel visualisation tools. Nucleic Acids Res 1998; 26: 205-213.
30. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
31. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlation with the growth inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-4300.
32. Rohr UP, Kronenwett R, Grimm D, Kleinschmidt J, Haas R. Primary human cell differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J Virol Methods 2002; 105: 265-275.
33. Swisher SG, Roth JA, Komaki R, Hicks M, Ro J, Dreiling L et al. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 2000; 19: 461a.
34. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000; 18: 609-622.
35. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750-1758.
36. Nawrocki ST, Sweeny-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004; 3: 59-70.
37. Kut V, Patel JD, Argiris A. Pemtrexed: a novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther 2004; 4: 511-522.
38. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-531.
39. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronized HeLa cells. Br J Cancer 1995; 71: 1194-1198.
40. Ling Y-H, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2Mphase arrest and apoptosis. Mol Cancer Ther 2002; 1: 841-849.
41. Fanucchi MP, Fossella F, Fidias P. Bortezomib±docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study. Am Soc Clin Oncol 2005; Abstract No: 7024.